Summit Therapeutics announced the opening of clinical trial sites on October 19, 2026, for a Phase II ivonescimab trial in previously untreated advanced clear cell renal cell carcinoma. The study, conducted with partner Akeso, will evaluate the antibody alone and in combinations against an established treatment regimen.
Key Takeaways
- The randomized Phase II study plans to enroll approximately 100 participants across the United States and China.
- Three ivonescimab-based regimens will be compared with nivolumab plus ipilimumab.
- The announcement marks site openings, not clinical results or regulatory approval.
Table of Contents
- Ivonescimab trial tests four treatment approaches
- A development milestone, not evidence of clinical benefit
- Conclusion
Ivonescimab trial tests four treatment approaches
Akeso’s Phase II study announcement identifies the international trial as SMT112-216 / AK112-216 / NCT07877194. It will assess safety and efficacy in patients with locally advanced or metastatic clear cell renal cell carcinoma who have not received prior systemic treatment.
The study is randomized and open-label. Participants will receive one of four regimens, allowing the companies to evaluate ivonescimab both as a standalone treatment and alongside other immunotherapies.
Ivonescimab targets PD-1 and VEGF. One combination pairs it with Akeso’s cadonilimab, a bispecific antibody targeting PD-1 and CTLA-4; another pairs it with ipilimumab. The comparator, nivolumab plus ipilimumab, is an established first-line treatment for advanced renal cell carcinoma.
| Item | Details |
|---|---|
| Investigational arm 1 | Ivonescimab plus cadonilimab |
| Investigational arm 2 | Ivonescimab plus ipilimumab |
| Investigational arm 3 | Ivonescimab monotherapy |
| Comparator arm | Nivolumab plus ipilimumab |
A development milestone, not evidence of clinical benefit
Clear cell renal cell carcinoma is the most common type of kidney cancer. The study expands the evaluation of ivonescimab into treatment options for patients whose advanced disease has not yet been treated systemically.
For Summit, a clinical-stage oncology company, opening sites advances its development program but does not establish that any experimental regimen is safer or more effective than the comparator. Those questions depend on results from the study.
The partners also have another kidney-cancer research effort underway: earlier in 2026, Summit announced a collaboration to evaluate ivonescimab with Arcus Biosciences’ HIF2α inhibitor casdatifan, including in first-line metastatic disease. That collaboration is separate from the newly opened four-arm Phase II study.
Conclusion
The next operational step is participant enrollment into the planned study. Neither the site-opening announcement nor the study design provides clinical outcomes, and the supplied announcements give no timetable for results.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
